Treatment of diabetic kidney disease: current and future targets

@inproceedings{Kim2017TreatmentOD,
  title={Treatment of diabetic kidney disease: current and future targets},
  author={Mi-kyung Kim},
  booktitle={The Korean journal of internal medicine},
  year={2017}
}
Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin system. However, the prevalence of DKD continues to increase and additional therapies are required to prevent or ameliorate the condition. Many drugs have been, or are being, developed to target the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Adiponectin for the treatment of diabetic nephropathy

  • The Korean journal of internal medicine
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 68 REFERENCES

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.

  • The Journal of pharmacology and experimental therapeutics
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

New therapeutic agents in diabetic nephropathy

  • The Korean journal of internal medicine
  • 2017
VIEW 2 EXCERPTS

American Diabetes Association . 9 : Microvascular complications and foot care

SJ Taler, R Agarwal, GL Bakris
  • Diabetes Care
  • 2016